There are three variants of coronaviruses (CoV) able to cause human deadly conditions, such as severe pneumonia and acute respiratory distress syndrome (ARDS). Their latent potential to become worldwide hazards was sadly proven with the COVID-19 pandemic. But their gravity goes beyond mortality rates, as many of those who survived infections developed a subsequent syndrome called post-acute sequelae of COVID (PASC), a condition with no current effective treatments available.
Our lab’s work aims to:
- Study virus-host interactions, in particular the effect of virus infections in innate immune response.
- Design new vaccines and antivirals that can protect against acute severe respiratory CoV infections, as well as help manage its sequels.